GlassScriptPhysician profile
Sandra Dennis
NPI 1174768485
$674.69
in general payments reported to CMS, 2019-2025
13 companies · $61.09 in 2025
The $61.09 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $216 · 2022: $170 · 2023: $85.71 · 2024: $142 · 2025: $61.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $289.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.59 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $112.61 | 2021-2024 | Jardiance, Emgality |
| Abbvie INC. | $92.06 | 2021-2023 | |
| Novo Nordisk INC | $65.23 | 2022-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $54.22 | 2022-2023 | Gardasil 9, Vaxelis, Proquad |
| Astrazeneca Pharmaceuticals LP | $53.07 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.98 | 2022 | |
| Phathom Pharmaceuticals, INC. | $25.70 | 2024 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.79 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $18.35 | 2021 | |
| Glaxosmithkline, LLC. | $16.03 | 2024 | Trelegy Ellipta |
| Amgen INC. | $15.06 | 2025 | Otezla, Repatha |
| Pfizer INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Dennis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.